CD4 and AIDS: We propose IRF-5 blockade as a possible therapeutic target to prevent memory CD4+ T cell loss in patients under ART and, more importantly, for patients who have a low CD4+ T cell recovery despite long-term ART that represent 20% of patients with a persistent risk to develop non-AIDS and AIDS comorbidities.